P/B
—
Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
$1.1B
Market Cap • 9/28/2026
2015
(11 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
0,1
BVPS
—
EPS
179,7
Market Cap
Market Cap
1,1B
EV
620M
EV/Revenue
0
EV/EBITDA
-4,2
EV/EBIT
-4,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-37,4%
Total Yield
-37,4%
Payout
0%
Retained Earnings
-1,4B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
-150%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
0,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
19,8%
CAGR OCF 5Y
20,1%
Leverage
N.D./EBITDA
3,1
Debt/Equity
0%
Current Ratio
19,1
Quick Ratio
18,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!